MedPath

Pegaptanib

Generic Name
Pegaptanib
Drug Type
Biotech
CAS Number
222716-86-1
Unique Ingredient Identifier
3HP012Q0FH

Overview

Pegaptanib is a polynucleotide aptamer. Pegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability. Pegaptanib was granted FDA approval on 17 September 2004.

Background

Pegaptanib is a polynucleotide aptamer. Pegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability. Pegaptanib was granted FDA approval on 17 September 2004.

Indication

For the treatment of neovascular (wet) age-related macular degeneration.

Associated Conditions

  • Neovascular Age-Related Macular Degeneration (nAMD)

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic Retinopathy
2012/05/02
NCT01589718
Phase 3
Withdrawn
Greater Houston Retina Research
Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium
2012/04/09
NCT01573572
Phase 4
Completed
Bausch & Lomb Incorporated
Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study
2011/12/06
NCT01486238
Phase 4
Completed
Valley Retina Institute
Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.
2011/01/21
NCT01281098
Phase 2
Completed
Association for Innovation and Biomedical Research on Light and Image
Observational Study Of The Long-Term Effect Of Macugen In Patients With Wet Age-Related Macular Degeneration
2010/11/22
NCT01245387
N/A
Completed
Pfizer
Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic Myopia
2010/10/11
NCT01218230
Not Applicable
Withdrawn
L.V. Prasad Eye Institute
Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema
2010/08/26
NCT01189461
Phase 3
Completed
Pfizer
A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema
2010/04/08
NCT01100307
Phase 3
Completed
Pfizer
Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice.
2009/03/09
NCT00858208
N/A
Completed
Pfizer
Long-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration
2009/02/18
NCT00845273
N/A
Completed
Pfizer

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy